Roche makes hostile takeover bid for life sciences group Illumina

Swiss drug giant Roche Holding on Wednesday made a hostile $5.7bn bid for DNA diagnostics company Illumina. Roche had previously attempted “multiple efforts” to start negotiations but Illumina refused to enter into “substantive discussion,” the company said.

The offering of $44.50 a share represents an 18 percent premium over Illumina’s closing price per share on Tuesday.

Roche said an acquisition of Illumina would provide benefits such as increased strength in the life sciences and diagnostics sector.

Print Friendly, PDF & Email

Author: Travis Esquivel

Travis Esquivel is an engineer, passionate soccer player and full-time dad. He enjoys writing about innovation and technology from time to time.

Share This Post On

Submit a Comment

Your email address will not be published. Required fields are marked *